Cadrenal Therapeutics Enters Warrant Inducement Financing Agreement

Cadrenal Therapeutics, Inc. ( (CVKD) ) just unveiled an update.

On March 31, 2026, Cadrenal Therapeutics entered into a warrant inducement agreement with a warrant holder from its November 4, 2024 private placement, leading the holder to exercise existing warrants for 571,430 shares at a reduced price of $4.50 per share, generating about $2.5 million in gross proceeds expected to close on April 1, 2026. In return, the company issued an equal number of new unregistered Series B-1 and Series B-2 warrants at the same exercise price, along with additional placement agent warrants to H.C. Wainwright & Co., a structure that raises near-term cash for working capital while layering in future potential dilution and reinforcing Cadrenal’s use of warrant-based financing in a challenging biotech capital environment.

The new warrants, exercisable for five years and eighteen months respectively after effectiveness of a resale registration statement, contain ownership caps, anti-dilution adjustments, cashless exercise rights if resale registration is unavailable, and protections in the event of fundamental transactions, shaping the future rights and economics for both the investor and the company. For 15 days after closing, Cadrenal agreed to limit new share or equivalent issuances and new registration filings, signaling a short-term constraint on further equity issuance that may offer modest support to existing shareholders while the company secures this incremental funding.

The most recent analyst rating on (CVKD) stock is a Sell with a $4.00 price target. To see the full list of analyst forecasts on Cadrenal Therapeutics, Inc. stock, see the CVKD Stock Forecast page.

Spark’s Take on CVKD Stock

According to Spark, TipRanks’ AI Analyst, CVKD is a Neutral.

The score is primarily weighed down by weak financial performance (no revenue, widening losses, and worsening cash burn that implies ongoing funding needs) and a clearly bearish technical setup (price far below key moving averages with negative MACD). Valuation provides limited support because the company is loss-making (negative P/E) and no dividend yield is available.

To see Spark’s full report on CVKD stock, click here.

More about Cadrenal Therapeutics, Inc.

Cadrenal Therapeutics, Inc. is a biopharmaceutical company focused on developing therapies in the cardiovascular and renal disease space. The company accesses capital markets through equity and warrant financings and targets investors in Nasdaq-listed small-cap life sciences, reflecting a reliance on structured securities to fund ongoing operations and working capital needs.

Average Trading Volume: 52,228

Technical Sentiment Signal: Sell

Current Market Cap: $11.97M

Find detailed analytics on CVKD stock on TipRanks’ Stock Analysis page.